Ascletis Pharma Stock Price To Book
ASCLF Stock | USD 1.04 0.12 13.04% |
Ascletis Pharma fundamentals help investors to digest information that contributes to Ascletis Pharma's financial success or failures. It also enables traders to predict the movement of Ascletis Pink Sheet. The fundamental analysis module provides a way to measure Ascletis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascletis Pharma pink sheet.
Ascletis |
Ascletis Pharma Company Price To Book Analysis
Ascletis Pharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Ascletis Pharma Price To Book | 1.58 X |
Most of Ascletis Pharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascletis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition |
Based on the latest financial disclosure, Ascletis Pharma has a Price To Book of 1.5764 times. This is 93.86% lower than that of the Healthcare sector and 73.9% lower than that of the Biotechnology industry. The price to book for all United States stocks is 83.42% higher than that of the company.
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
All Next | Launch Module |
Ascletis Fundamentals
Return On Equity | -0.0632 | |||
Return On Asset | -0.053 | |||
Profit Margin | (2.24) % | |||
Operating Margin | (3.11) % | |||
Current Valuation | 116.15 M | |||
Shares Outstanding | 1.09 B | |||
Shares Owned By Insiders | 67.02 % | |||
Shares Owned By Institutions | 1.94 % | |||
Price To Book | 1.58 X | |||
Price To Sales | 7.61 X | |||
Revenue | 76.88 M | |||
Gross Profit | 39.17 M | |||
EBITDA | (169.35 M) | |||
Net Income | (199.02 M) | |||
Cash And Equivalents | 2.5 B | |||
Cash Per Share | 2.28 X | |||
Total Debt | 2.75 M | |||
Debt To Equity | 0 % | |||
Current Ratio | 28.93 X | |||
Book Value Per Share | 2.50 X | |||
Cash Flow From Operations | (146.93 M) | |||
Earnings Per Share | (0.03) X | |||
Number Of Employees | 315 | |||
Beta | 0.81 | |||
Market Capitalization | 672.93 M | |||
Total Asset | 2.83 B | |||
Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.